AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. Sells 4,060 Shares

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

AngioDynamics Stock Down 2.7 %

ANGO stock opened at $12.43 on Friday. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $13.13. The company has a fifty day simple moving average of $8.75 and a two-hundred day simple moving average of $7.66. The firm has a market capitalization of $503.04 million, a P/E ratio of -2.21 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. During the same quarter last year, the business earned ($0.05) earnings per share. AngioDynamics’s quarterly revenue was down .1% compared to the same quarter last year. As a group, analysts anticipate that AngioDynamics, Inc. will post -0.36 EPS for the current year.

Institutional Investors Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quarry LP raised its stake in shares of AngioDynamics by 75.1% in the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 2,594 shares during the period. CWM LLC raised its stake in shares of AngioDynamics by 981.3% in the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after acquiring an additional 8,832 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of AngioDynamics in the third quarter valued at $86,000. Mackenzie Financial Corp purchased a new stake in shares of AngioDynamics in the second quarter valued at $80,000. Finally, SG Americas Securities LLC purchased a new stake in shares of AngioDynamics in the third quarter valued at $103,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Canaccord Genuity Group dropped their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th. HC Wainwright upped their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.